Arecor Limited announced it has been awarded a £2.8mln grant from Innovate UK to support the Phase II development of AT247.
The candidate is an ultra-rapid acting insulin product based on the biopharma company’s proprietary Arestat technology platform.
WATCH: Arecor licenses first formulation to partner Inhibrx, taking their lung disease product to clinic
The formulation was designed to accelerate insulin absorption, post injection, to achieve more effective and controlled management of blood glucose levels.
The development programme, supported by the grant, will include a Phase II clinical trial to compare the glycaemic control, safety and tolerability of AT247 with Fiasp when administered by insulin pump over an extended period.
Continuous glucose monitoring will allow the assessment of time spent with blood glucose level in a healthy range, the control of which is crucial for avoiding episodes of hyper- and hypo- glycaemia and delivering positive long term health outcomes for people with Type 1 Diabetes.
This Phase II clinical trial is expected to commence in the first half of 2022 and is part of an extensive development programme designed to demonstrate the benefits of AT247 as a potentially best-in-class ultra-rapid acting insulin.
Despite significant advances in treatment options, 79% of people with diabetes live with severe complications due to time spent outside of their target blood glucose range, Arecor noted.
It has been shown that blood glucose control and time in range can be improved when patients are using an automated insulin delivery system, where blood glucose is continuously measured, whilst an algorithm calculates insulin requirements based on real-time blood glucose which is then automatically delivered by a pump.
AT247 has the potential to be an ideal pump insulin enabling a closed loop artificial pancreas for patients with Type I diabetes to be realised, the private firm added.
“We are proud that Innovate UK has, through their thorough technical and commercial review process, chosen to invest in our research from across the very best of British science,” said chief executive Sarah Howell in a release.
“The substantial grant we are announcing today provides additional non-dilutive funding to support and accelerate AT247’s Phase II development.”